Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + CAPOX for Locally Advanced MSS Rectal Cancer
NCT06254521Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Feb 2024
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in rectal cancer, sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoint: Pathological Complete Response Rate. Started Feb 2024; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06254521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06254521.